Global Depression Treatment Therapy Market Report 2022-2028: Selective Serotonin Reuptake Inhibitors (SSRIs) Hold Significant Share
10 oct. 2022 06h43 HE
|
Research and Markets
Dublin, Oct. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
Nexstim NBS 5+ System Continues to Generate Interest in the US
06 oct. 2022 05h00 HE
|
Nexstim Oyj
Press release, Helsinki, 6 October 2022 at 12 PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs....
Pacific Solstice Offers Mental Health Program That Quickens Progress in Junior High and High School Students
09 sept. 2022 09h00 HE
|
Pacific Solstice
MISSION VIEJO, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- "Recent national surveys of young people have shown alarming increases in the prevalence of certain mental health challenges— in 2019, one...
Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital
02 juin 2022 03h00 HE
|
Nexstim Oyj
Press release, Helsinki, 2 June 2022 at 10 AM (EEST) Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") today...
Nexstim Receives an NBS 5+ System Order from a US Customer
06 avr. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 6 April 2022 at 9 AM (EEST) Nexstim Receives an NBS 5+ System Order from a US Customer Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received...
Nexstim Receives a System Upgrade Order from a Customer in Finland
16 févr. 2022 02h30 HE
|
Nexstim Oyj
Press release, Helsinki, 16 February 2022 at 9:30 AM (EET) Nexstim Receives a System Upgrade Order from a Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received...
Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd
14 févr. 2022 02h00 HE
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi neuropsykiatrisien häiriöiden hoitoon
14 févr. 2022 02h00 HE
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 14.2.2022 klo 9.00 (EET) Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi...
Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders
14 févr. 2022 02h00 HE
|
Nexstim Oyj
Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...
Nexstim Receives an NBS 5+ System Order from a Customer in the US
24 janv. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 24 January 2022 at 9 AM (EET) Nexstim Receives an NBS 5+ System Order from a Customer in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having...